Brief: Diffusion Pharmaceuticals Sees Significant Progress In Its Strategic Review Process

CervoMed

14/11/2022 12:56

Nov 14 (Reuters) - Diffusion Pharmaceuticals Inc
 DFFN.O :
    * DIFFUSION PHARMACEUTICALS SEES SIGNIFICANT PROGRESS IN ITS
STRATEGIC REVIEW PROCESS
    * DIFFUSION PHARMACEUTICALS INC - ON IN ACTIVE BIDDING STAGE
AND
ENCOURAGED BY RESPONSE TO STRATEGIC REVIEW PROCESS
    * DIFFUSION PHARMACEUTICALS INC - ON IN ACTIVE BIDDING STAGE
AND
ENCOURAGED BY RESPONSE TO STRATEGIC REVIEW PROCESS
    * DIFFUSION PHARMACEUTICALS INC -  BOARD OF DIRECTORS
REJECTS
UNSOLICITED OFFER FOR COMPANY BY CLIENT OF INVESTMENT BANK
LIFESCI CAPITAL
    * DIFFUSION PHARMACEUTICALS INC - LIFESCI-AFFILIATED FUND
COMMENCES PROXY CONTEST FOR CONTROL OF DIFFUSION BOARD FOLLOWING
REJECTION OF CLIENT'S OFFER
    * DIFFUSION PHARMACEUTICALS INC - ON NOVEMBER 7, 2022,
LIFESCI
NOTIFIED PLANS TO NOMINATE ITS OWN SLATE OF DIRECTORS FOR
ELECTION AT 2022 ANNUAL MEETING

Source text for Eikon:  ID:nGNX3TzZ93 
Further company coverage:  DFFN.O 
 ((Reuters.Briefs@thomsonreuters.com;))